Vision-Sciences Inc. (CGNT) Raised to Hold at Zacks Investment Research
According to Zacks, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York. “
Separately, Roth Capital upgraded Vision-Sciences from a neutral rating to a buy rating in a research report on Wednesday, September 7th.
Vision-Sciences (NASDAQ:CGNT) opened at 1.68 on Tuesday. The stock’s market cap is $43.92 million. Vision-Sciences has a 12-month low of $0.71 and a 12-month high of $1.99. The stock’s 50 day moving average price is $1.55 and its 200 day moving average price is $1.16.
Vision-Sciences (NASDAQ:CGNT) last released its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by $0.11. Vision-Sciences had a negative return on equity of 27.43% and a negative net margin of 13.99%. Analysts forecast that Vision-Sciences will post ($0.21) EPS for the current fiscal year.
A hedge fund recently raised its stake in Vision-Sciences stock. Amici Capital LLC boosted its stake in shares of Vision-Sciences Inc. (NASDAQ:CGNT) by 14.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,415,589 shares of the medical device company’s stock after buying an additional 180,689 shares during the period. Amici Capital LLC owned approximately 5.58% of Vision-Sciences worth $1,557,000 as of its most recent SEC filing. 30.43% of the stock is owned by institutional investors.
Cogentix Medical, Inc, formerly Vision-Sciences, Inc, is a medical device company. The Company designs, develops, manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, EndoSheath technology. The Company produces and markets Endoscopes, such as cystoscopes, ureteroscopes, laryngoscopes, otoscopes, sinuscopes, trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use, and digital processing units (DPU).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vision-Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vision-Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.